A European clinical trial to evaluate four experimental treatments for COVID-19 starts this weekend. Coordinated by Inserm as part of the Reacting consortium, this trial will include at least 800 French patients with severe forms of COVID-19. ...
At a time when the Sars-CoV-2 epidemic is continuing to spread, France’s Alliance for Life Sciences and Health (Aviesan) is mobilizing to accelerate research into the virus and COVID-19 disease through REACTing – a consortium coordinated by Inserm. The Scientific Advisory Board ...
Each year, some twenty cases of Staphylococcal toxic shock syndrome linked to tampon use are reported in France. Characterized by various symptoms, such as high fever and skin rash, it can lead to multiple-organ failure and death in the most extreme cases. ...
In previous years, various studies have established a link between psychological stress and reduced immune defenses, but the mechanisms involved remained poorly elucidated. ...
It is world’s third most common tropical mycobacterial disease after tuberculosis and leprosy. Caused by Mycobacterium ulcerans, it leads to the destruction of skin tissue and the development of large ulcers which can affect entire limbs right down to the bone. ...
Researchers have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection. These results open up new prospects for the prevention and treatment of bacterial pneumonia, a major cause of ...
14.09.2021
Press release
09.09.2021
Press release
16.09.2021
Press release
13.09.2021